Hormonal
GLP-1 receptor agonist therapies significantly reduce total cardiovascular events, major adverse cardiovascular events (MACE), and all-cause mortality in nondiabetic individuals with overweight or obesity compared to placebo.
For nondiabetic adults who are overweight or obese, using GLP-1 receptor agonist therapies (such as semaglutide, tirzepatide, or liraglutide) significantly lowers the risk of heart attacks, strokes, and death from any cause compared to placebo. This benefit exists independently of diabetes status, suggesting these drugs should be considered for cardiovascular risk reduction in this population, not just for weight loss.
Compared to placebo, GLP-1RA-based therapies significantly reduced the risk of total cardiovascular events (relative risk: 0.81, 95% confidence interval [CI]: [0.76, 0.87]), major adverse cardiovascular events (0.80, [0.72, 0.89]), myocardial infarction (0.72, [0.61, 0.85]), and all- cause mortality (0.81, [0.71, 0.93]).
Why this rating
Based on a meta-analysis of 29 randomized controlled trials involving 37,348 participants.
Source
Efficacy of <scp>GLP</scp>‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Yue Yin et al. · Journal of Diabetes · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →